SG11202111429UA - Use of an anti-cd19 antibody to treat autoimmune disease - Google Patents
Use of an anti-cd19 antibody to treat autoimmune diseaseInfo
- Publication number
- SG11202111429UA SG11202111429UA SG11202111429UA SG11202111429UA SG11202111429UA SG 11202111429U A SG11202111429U A SG 11202111429UA SG 11202111429U A SG11202111429U A SG 11202111429UA SG 11202111429U A SG11202111429U A SG 11202111429UA SG 11202111429U A SG11202111429U A SG 11202111429UA
- Authority
- SG
- Singapore
- Prior art keywords
- antibody
- autoimmune disease
- treat autoimmune
- treat
- disease
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962838093P | 2019-04-24 | 2019-04-24 | |
| US201962843096P | 2019-05-03 | 2019-05-03 | |
| US201962858495P | 2019-06-07 | 2019-06-07 | |
| PCT/US2020/029613 WO2020219743A2 (en) | 2019-04-24 | 2020-04-23 | Use of an anti-cd19 antibody to treat autoimmune disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202111429UA true SG11202111429UA (en) | 2021-11-29 |
Family
ID=72940915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202111429UA SG11202111429UA (en) | 2019-04-24 | 2020-04-23 | Use of an anti-cd19 antibody to treat autoimmune disease |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220204617A1 (en) |
| EP (1) | EP3959241A4 (en) |
| JP (1) | JP2022529743A (en) |
| KR (1) | KR20220004113A (en) |
| CN (1) | CN113939532A (en) |
| AU (1) | AU2020263418A1 (en) |
| BR (1) | BR112021020924A2 (en) |
| CA (1) | CA3136487A1 (en) |
| IL (1) | IL287385A (en) |
| MX (1) | MX2021012870A (en) |
| SG (1) | SG11202111429UA (en) |
| WO (1) | WO2020219743A2 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3809260A1 (en) * | 2019-10-18 | 2021-04-21 | Siemens Healthcare GmbH | System and method for monitoring production systems |
| MX2022016236A (en) * | 2020-06-30 | 2023-03-29 | Viela Bio Inc | Methods of treating neuromyelitis optica spectrum disorder. |
| AU2021368769A1 (en) * | 2020-10-29 | 2023-06-08 | Viela Bio, Inc. | Use of an anti-cd19 antibody to treat autoimmune disease |
| JP2024518410A (en) * | 2021-05-07 | 2024-05-01 | ビエラ バイオ インコーポレイテッド | Use of anti-CD19 antibodies to treat myasthenia gravis |
| WO2024025602A1 (en) | 2022-07-27 | 2024-02-01 | Viela Bio, Inc. | Inebilizumab and methods of using the same for sustained b-cell depletion |
| WO2024155810A1 (en) * | 2023-01-20 | 2024-07-25 | Viela Bio, Inc. | Anti-cd19 binding agents for the treatment and prevention of immune mediated necrotizing myopathy |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101534859B (en) * | 2006-09-08 | 2017-06-09 | 米迪缪尼有限公司 | Humanized anti-cd 19 antibodies and its application in treating cancer, transplantation disease and autoimmunity disease |
| EP2066349B1 (en) * | 2006-09-08 | 2012-03-28 | MedImmune, LLC | Humanized anti-cd19 antibodies and their use in treatment of tumors, transplantation and autoimmune diseases |
| CN102413839A (en) * | 2009-03-06 | 2012-04-11 | 医学免疫有限责任公司 | Humanized anti-CD19 antibody formulations |
| RU2014141056A (en) * | 2012-03-12 | 2016-05-10 | МЕДИММЬЮН, ЭлЭлСи | TREATMENT OF MULTIPLE SCLEROSIS BY ANTIBODY TO CD19 |
| GB201401465D0 (en) * | 2014-01-29 | 2014-03-12 | Roach Arthur H | Use of cladribine for treating autoimmune inflammatory disease |
-
2020
- 2020-04-23 BR BR112021020924A patent/BR112021020924A2/en unknown
- 2020-04-23 SG SG11202111429UA patent/SG11202111429UA/en unknown
- 2020-04-23 WO PCT/US2020/029613 patent/WO2020219743A2/en unknown
- 2020-04-23 AU AU2020263418A patent/AU2020263418A1/en active Pending
- 2020-04-23 JP JP2021563213A patent/JP2022529743A/en active Pending
- 2020-04-23 US US17/606,306 patent/US20220204617A1/en active Pending
- 2020-04-23 CN CN202080030819.6A patent/CN113939532A/en active Pending
- 2020-04-23 MX MX2021012870A patent/MX2021012870A/en unknown
- 2020-04-23 EP EP20794203.8A patent/EP3959241A4/en active Pending
- 2020-04-23 CA CA3136487A patent/CA3136487A1/en active Pending
- 2020-04-23 KR KR1020217038068A patent/KR20220004113A/en active Search and Examination
-
2021
- 2021-10-19 IL IL287385A patent/IL287385A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020219743A2 (en) | 2020-10-29 |
| EP3959241A2 (en) | 2022-03-02 |
| KR20220004113A (en) | 2022-01-11 |
| JP2022529743A (en) | 2022-06-23 |
| US20220204617A1 (en) | 2022-06-30 |
| AU2020263418A1 (en) | 2021-11-11 |
| BR112021020924A2 (en) | 2022-04-19 |
| CA3136487A1 (en) | 2020-10-29 |
| IL287385A (en) | 2021-12-01 |
| CN113939532A (en) | 2022-01-14 |
| WO2020219743A3 (en) | 2020-12-10 |
| EP3959241A4 (en) | 2023-01-25 |
| MX2021012870A (en) | 2022-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287385A (en) | Use of an anti-cd19 antibody to treat autoimmune disease | |
| IL277858A (en) | Antibodies specific to human nectin4 | |
| IL279053A (en) | Anti-pvrig/anti-tigit bispecific antibodies and methods of use | |
| CL2018000728A1 (en) | Humanized human anti-cd19 antibodies and methods of use | |
| PT3468997T (en) | Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b | |
| IL277217A (en) | Use of anti-il-36r antibodies for treatment of inflammatory bowel disease | |
| IL271266A (en) | Use of anti cd70 antibody argx-110 to treat acute myeloid leukaemia | |
| IL281449A (en) | Anti-ifnar1 antibodies for treating autoimmune diseases | |
| IL278222A (en) | Integration of high frequency reconstruction techniques with reduced post-processing delay | |
| HK1249016A1 (en) | Compositions and methods for using anti-il-34 antibodies to treat neurological diseases | |
| EP3716949A4 (en) | Methods of treating autoimmune disease | |
| ZA202104356B (en) | Monoclonal antibodies that bind specifically to human trbv9 | |
| GB201804724D0 (en) | Method of diagnosing cceliac disease | |
| EP3837286A4 (en) | Antibodies to human znt8 | |
| EP3523333C0 (en) | Anti-ceacam6 antibodies and methods of use | |
| IL284807A (en) | Antibodies specific to human nectin-2 | |
| IL283136A (en) | Antibodies to mucin-16 and methods of use thereof | |
| EP4237447A4 (en) | Use of an anti-cd19 antibody to treat autoimmune disease | |
| MX2015015232A (en) | Monoclonal antibody directed against cxcr5. | |
| IL273538A (en) | Anti-trkb monoclonal antibodies and methods of use | |
| EP3615561C0 (en) | Variants of human bmp7 protein | |
| IL286099A (en) | Methods of treating disease with levoketoconazole | |
| IL269419A (en) | Treatment of lupus using humanized anti-cxcr5 antibodies | |
| GB201811375D0 (en) | Treatment of autoimmune disease | |
| GB201804603D0 (en) | Treatment of antiretroviral disease |